bezafibrate has been researched along with Carcinoma, Hepatocellular in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parés, A; Reig, A; Sesé, P | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Imawari, M; Iwamoto, J; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Saito, Y; Takikawa, H | 1 |
| Binsack, R; Dörge, L; Stegmeier, K; Völkl, A | 1 |
| Börchers, T; Buhlmann, C; Rolf, B; Spener, F; Wolfrum, C | 1 |
| Ihara, H; Nagai, N; Nakajima, T; Suzuki, Y; Takada, A; Takada, Y; Taminato, T; Urano, T | 1 |
1 trial(s) available for bezafibrate and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholagogues and Choleretics; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Lipids; Liver; Liver Cirrhosis, Biliary; Liver Neoplasms; Male; Middle Aged; PPAR alpha; Pregnane X Receptor; Receptors, Steroid; Treatment Failure; Treatment Outcome; Ursodeoxycholic Acid | 2013 |
4 other study(ies) available for bezafibrate and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Topics: Alkaline Phosphatase; Bezafibrate; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Humans; Hypolipidemic Agents; Jaundice; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Pruritus; Ursodeoxycholic Acid; Visual Analog Scale | 2018 |
Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells.
Topics: Acute-Phase Reaction; Animals; Bezafibrate; Biological Transport; Carcinoma, Hepatocellular; Cattle; Dose-Response Relationship, Drug; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fetal Blood; Fibrinogen; Humans; Intracellular Fluid; Lectins; Liver Neoplasms; Neoplasm Proteins; Precipitin Tests; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake.
Topics: Bezafibrate; Carcinoma, Hepatocellular; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Humans; Myelin P2 Protein; Neoplasm Proteins; Peroxisome Proliferators; Pyrimidines; RNA, Antisense; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells.
Topics: Bezafibrate; Blotting, Northern; Carcinoma, Hepatocellular; Chromans; Culture Media, Conditioned; Dose-Response Relationship, Drug; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Humans; Insulin; Liver Neoplasms; Oleic Acid; Plasminogen Activator Inhibitor 1; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Up-Regulation | 2001 |